Synlogic Investor Relations Material

Synlogic Inc. is a biotechnology company focused on developing synthetic biotic medicines, which are engineered living organisms designed to treat metabolic and other diseases. The company’s platform uses genetically modified bacteria to deliver therapeutic effects within the human body, targeting diseases such as phenylketonuria (PKU) and other metabolic disorders. Synlogic’s approach aims to address unmet medical needs through innovative treatments that leverage the power of synthetic biology. The company is headquartered in Cambridge, Massachusetts, and its shares are listed on the NASDAQ.